Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan (Non-Buscopan)

October 13, 2020 updated by: Taipei Veterans General Hospital, Taiwan

Antiperistaltic Effect and Safety of L-menthol and Placebo for Upper GI Endoscopy in the Elderly With Contraindication to Buscopan: a Prospective, Randomized, Double-blind Study

antiperistaltic effect and safety of L-menthol versus placebo for upper GI endoscopy in elderly patient with contraindication to Buscopan: randomized study

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Endoscopy is a important tool for diagnosis and treatment of gastrointestinal diseases. Effective inhibition of gastrointestinal motility during examination is important to achieve good results and quality.

Traditionally, hyoscine-N-butylbromide (Buscopan) is the most commonly used drugs that inhibit intestinal peristalsis. But the side effects of drugs were mentioned in many studies, such as arrhythmia, increased glaucoma, dysuria in patients who have benign prostatic hypertrophy and allergic reactions, and may even cause anaphylactic shock. Peppermint oil is the extract of the natural plant (Mentha X piperita L) which was growth in North America and Europe. L-menthol is main component of peppermint oil. In animal experiments, peppermint oil had effect of calcium channel blockers and cause gastrointestinal smooth muscle relaxing effect. Clinically, peppermint oil preparations were used to relieve stress headache, non-ulcer dyspepsia and irritable bowel syndrome. The oral or intestinal local spraying of peppermint oil or L-menthol showed inhibition of intestinal peristalsis in many studies, and improved colonoscopy, barium enema, retrograde cholangiography , and upper gastrointestinal endoscopy examination.

With the aging of the population of Taiwan and the universality of endoscopy for elderly patients, the safety of endoscopy in elderly patients has more and more attention. According to ASGA guidelines, age is not a contraindication for endoscopy. But 50% of elderly patients have contraindications for hyoscine-N-butylbromide use. Therefore, effort to find alternative medicine to improve quality of endoscopy in elderly patients is necessary. Therefore, the investigators design a research for comparing effect and safety of L-menthol and placebo in elderly patients who have contraindication of hyoscine-N-butylbromide.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 11217
        • Recruiting
        • Taipei Veterans General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • >65 years old
  • routine endoscopic examination
  • Contraindication to Buscopan(such as arrhythmia, glaucoma, benign prostatic hyperplasia, ischemic heart disease...)

Exclusion Criteria:

  • Status post gastric or duodenal surgery
  • The patient with critical illness are not suitable for the endoscopic examination
  • Upper gastrointestinal bleeding
  • Gastric tumor
  • Gastric or duodenal ulcers are larger than 2 cm
  • Severe pyloric obstruction or deformity
  • Cancer patients received chemotherapy or radiation therapy
  • Had peppermint allergy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Other Names:
  • Peppermint oil
PLACEBO_COMPARATOR: Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Other Names:
  • Olive oil

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peristaltic grade
Time Frame: 10 mins
Grade 1: no peristalsis; grade 2: mild peristalsis; grade 3: moderate peristalsis; grade 4: vigorous peristalsis; grade 5: markedly vigorous peristalsis.
10 mins

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pylorus contraction ratio
Time Frame: 3 mins
Contraction ratio (%)= [(maximal pyloric ring diameter - minimal pyloric ring diameter)/minimal pyloric ring diameter] x 100
3 mins
Pylorus opening ratio: maximum and minimum
Time Frame: 3 mins
Opening ratio (%) = [(pyloric ring diameter after administration of the antispasmodic agent - pyloric ring diameter before administration of the antispasmodic agent) / pyloric ring diameter before administration of the antispasmodic agent] x 100
3 mins
Adverse effect of patients
Time Frame: 48 hours
record all adverse effect after study, include abdominal pain, heart burn, headache, allergy, etc.
48 hours
VAS score of patient about procedure
Time Frame: 10 mins
VAS score 1-10 about the painful sensation of patient during procedure
10 mins
Satisfaction of endoscopist
Time Frame: 10 mins
Four score was evaluated: very easy, easy, slightly difficult and difficult about the procedure due to gastric spasm
10 mins

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2012

Primary Completion (ANTICIPATED)

December 1, 2020

Study Completion (ANTICIPATED)

December 1, 2020

Study Registration Dates

First Submitted

October 22, 2013

First Submitted That Met QC Criteria

October 13, 2020

First Posted (ACTUAL)

October 20, 2020

Study Record Updates

Last Update Posted (ACTUAL)

October 20, 2020

Last Update Submitted That Met QC Criteria

October 13, 2020

Last Verified

October 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Upper Gastrointestinal Endoscopy

Clinical Trials on L-menthol

Subscribe